RIO~Eu: Effect on Insulin Resistance (HOMA) L.Van Gaal, Lancet 2005; 365: 1389-97 ITT, LOCF: R5 mg v. placebo: ns R20 mg v. placebo: p=0.003 1 yearBas
{"Image DocumentName": "RIO~Diabetes: Change in HbA1c", "Image ImageDescription": "ITT, LOCF. % units. Placebo. Rimonabant 5 mg. Rimonabant 20 mg. (Mean \uf0b1 SD) n=317. n=330. n=315. Baseline. 7.2 \uf0b1 \uf0b1 0.8. Year \uf0b1 \uf0b1 \uf0b10.9. Change. 0.1 \uf0b1 \uf0b1 \uf0b1 0.8. Difference rimonabant. v. placebo (SEM) -0.2 (0.1)  -0.7 (0.1)    p=   p< COMPLETERS: R5mg v. Placebo : -0.1% v. +0.1%, p= R20mg v. Placebo : -0.7% v. +0.1%, p<0.001.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}